Proteomics

The future of precision medicine

As medical professionals search for new ways to personalize diagnosis and treatment of disease, RPB-supported researchers at the University of Iowa have already put into practice what may be the next big step in precision medicine: personalized proteomics.

Photo: The future of precision medicine

Proteomics is the large-scale analysis of all the proteins in a cell type, tissue type, or organism. In contrast to genomics, which shows how genetic differences can indicate a person's potential for developing a disease over a lifetime, proteomics takes a real-time snapshot of a patient's protein profile during the disease. Doctors can use this information to tailor diagnosis and initiate treatment, sometimes long before a conventional diagnosis even begins to home in on a cause.

"Proteomics allows us to create a precision molecular diagnosis that's totally personalized for the patient," says Vinit Mahajan, M.D., Ph.D., UI clinical assistant professor of ophthalmology and visual sciences, and recipient of a 2011 RPB Career Development Award.

Mahajan's lab recently used proteomics to devise a successful treatment strategy for a patient with uveitis, a potentially blinding eye disease that can have many causes, making it particularly difficult to diagnose and treat effectively. The patient had been losing vision in one eye because of relapsing inflammation and swelling in the retina, with a buildup of scar tissue. The cause was unknown, so the treatment had consisted of a trial-and-error approach based on a clinical observation of the symptoms. "Right now, there is no precision medicine for this kind of disease," Mahajan says.

Mahajan and his team then performed a proteomic analysis of fluid taken from the patient's eye and compared that protein profile to profiles of other patients' eye fluid. Gabriel Velez, a graduate student in Mahajan's lab, spotted a pattern that closely resembled those of two other patients who were known to have an autoimmune disorder that produces antibodies against the retina.

"Her symptoms didn't look exactly like the standard clinical diagnosis for that disease," says Nathaniel Roybal, M.D., Ph.D., a vitreoretinal surgical fellow working with Mahajan. "She was missing many features. But based on this pattern that we saw, we ordered a lab test to check if she makes anti-retinal antibodies. And sure enough, the test showed that she did. So we changed how we treated her."

Mahajan performed surgery and implanted a device that releases a steroid into the eye. The patient's vision improved, and she no longer has relapses.

Alexander G. Bassuk, M.D., Ph.D., UI associate professor of pediatrics, who co-authored the paper, says the value of personal proteomics extends beyond uveitis. "We are using this platform to address other kinds of eye and inflammatory diseases where the best diagnosis and therapies for individual patients remain inadequate," Bassuk says.

While proteomics is being studied elsewhere, primarily for diagnostics, Mahajan says the UI implementation is unique because it uses a "whole-patient" approach that coordinates the collection, transport, storage, coding, and analysis of samples in a way that can directly and efficiently improve patient care. "We were able to combine surgery and science and intelligently go back to the patient to decide on the optimal therapy," Mahajan says. "This is personalized precision medicine. It's the next step."


Source: Research to Prevent Blindness

26.04.2016

Read all latest stories

Related articles

Photo

Breast cancer

Pre-treatment with targeted drugs reduces need for radical surgery

Extensive surgery involving mastectomy and removal of several lymph nodes can be safely avoided for more women with some types of breast cancer, if they receive targeted drugs before surgery,…

Photo

A map to the heart

The meaning of heart geometry in surgery

Geometry is often referenced for matters of the heart. Marriage has been described as “two parallel lines,” and others have compared love to an “irrational equation” or as unending as…

Photo

Investment

Curetis expands its diagnostic platform

Curetis N.V. and the European Investment Bank (EIB) today announced that the EIB granted Curetis a EUR 25 million senior, unsecured loan. The financing is the first growth capital loan under the…

Related products

Atlas Genetics - Atlas Genetics io system

Infectious diseases testing

Atlas Genetics - Atlas Genetics io system

Atlas Genetics Ltd
DiaSys Diagnostic Systems - InnovaStar

Clinical chemistry

DiaSys Diagnostic Systems - InnovaStar

DiaSys Diagnostic Systems GmbH
Eppendorf – Mastercycler nexus X2

Research Use Only (RUO)

Eppendorf – Mastercycler nexus X2

Eppendorf AG